Antipsychotic dose reduction in young people with stable, first-episode psychosis may improve long-term functional recovery, cognitive function, and quality of life compared to standard maintenance, despite a higher initial risk of relapse. Studies indicate that lowering doses, such as in the REDUCE study, helps minimize side effects and supports better vocational and social outcomes, with long-term relapse rates becoming comparable to maintenance groups.
Key Findings on Dose Reduction:
Key Findings on Dose Reduction:
- Improved Functional Recovery: Research shows that while high doses prevent relapse, they do not necessarily improve day-to-day functioning (e.g., employment, relationships) and may hinder it.
- Long-term Outcomes: A 7-year follow-up study revealed that, despite higher relapse rates in the first two years, individuals who tapered medication had significantly better functional improvement and higher rates of recovery in the long term.
- Cognitive Benefits: Gradual tapering is associated with improved cognitive performance compared to maintaining fixed, high doses.
- Safety Profile: Gradual reduction (e.g., 25% reduction every 6 months) allows for the identification of the lowest effective dose and reduces the burden of side effects like metabolic changes or sedation.
- Process: Reduction should be gradual and carefully monitored for signs of relapse.
- Target Population: This approach is generally targeted at young people who have achieved remission from their first episode of psychosis.
- Risks: The main risk is the re-emergence of symptoms, which may require rapid, temporary increases in dosage.
Last edited: